<div class="container">
    <div class="row">
        <div id="speaker-detail" class="col-lg-6 col-lg-offset-3">
            <div class="row">
                <button title="Close (Esc)" type="button" class="mfp-close">×</button>
                <div class="col-md-4 col-lg-4">
                    <img class="img-responsive" src="img/speaker_504.jpg" alt="" />
                    <br />
                </div>
                <div class="col-md-8 col-lg-8">
                    <h2>Ko-Chung Lin, Ph.D. 林國鐘 博士</h2>
                    <h3>Founder and CEO</h3>
                    <p>* Received his Ph.D. from the University of Missouri, postdoctoral research at the University of Michigan</p>
                    <p>* More than 20 years of successful experience in drug discovery and development</p>
                    <p>* Worked at Monsanto-Searle (US) on HIV protease inhibitor project resulting in an AIDS drug on the market; and at Biogen (US), where Lin led the team to discover their first drug candidate that was later licensed to Merck. He’s also the lead inventor Biogen’s PEG-IFN b (Plegridy)</p>
                    <p>* Inventor of 50 patents</p>
                </div>
                <div>
                    <p><a href="http://www.pharmaessentia.com" target="new">PharmaEssentia Corporation 藥華醫藥</a></p>
                    <p>PharmaEssentia Corporation aims to deliver efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to our stakeholders. At PharmaEssentia, our mission is a never-ceasing commitment to the improvement of health and quality of life. PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading biotechnology and pharmaceutical companies in the US, with a goal to develop treatments for myeloproliferative neoplasms, hepatitis and oncology.
                    </p>
                </div>
            </div>
        </div>
    </div>
